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Abstract Indocyanine green is a fluorescent molecule with
wide ranging applications in minimally invasive urological
surgery. This article explores the utility of ICG assisted
intraoperative fluorescence in robotic urology.
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Indocyanine green (ICG) is a fluorescent molecule [1]. Inci-
dent infrared light of wavelength 780 nm provokes
detectable photon emission at 820–830 nm [1]. Alongside a
high definition camera and software imposed pseudo-colour,
intravenously delivered ICG may be used to identify vessel
perfusion and differentiate tissue density [2–4]. Indocyanine
green was initially developed in the 1955 by Kodak photog-
raphy, and received FDA approval in 1959 [5, 6]. Indocyanine
green has a favourable safety profile, with an adverse event
rate of 0.34 % including nausea, vomiting, and rarely shock [1
in 300,000]) [7]. The use of ICG is established in ophthal-
mology, dermatology, and cardiology for vascular identifi-
cation [8, 9]. This articlewill summarise the current and future
applications of ICG in robotic urology, with the da Vinci
robot (dVSS), (Intuitive Surgical Systems, Sunnyvale, CA,
USA) with emphasis placed on the intraoperative identifica-
tion of vascular and oncological tissue. Notably, ICG is a
cheap consumable, and infrared endoscopic equipment is
widely available in contemporary dVSS systems (Firefly in
the DaVinci Xi).
A historical perspective of intraoperative imaging with
fluorescent dye is necessary to describe intra-opera-
tive imaging advances from the 20th century applicable to
modern robotic surgery. In 1947, seminal workwas conducted
by neurosurgeonGeorgeMoore at theUniversity ofMinnesota
Medical School. Moore described the use of fluorescein, a
fluorophore, to identify intracranial neoplastic tissue in the
journal Science [10]. By 1948, Moore had performed a case
series of 46 patients with mixed intracranial tumours [11].
Intraoperatively, he injected tumour with dye, identifying 44
tumours (96 %) correctly asmalignant [11].Moorewent so far
as to describe resection of remaining tissue based on fluores-
cent activity, thereby intraoperatively resecting positive sur-
gical margins [11]. He also radiolabelled diiodofluorescein
with iodine isotope 131 to detect gamma radiation from the
accumulation of dye at malignant tissue [11].
Complex pelvic surgery has been revolutionised by the
dVSS [12]. Wide adoption of the dVSS for radical
prostatectomy and partial nephrectomy has followed, due
to enhanced degrees of movement from the robotic wrist,
tremor reduction, enhanced ergonomics, greater magnifi-
cation, and the ability to operate in a closed anatomical
space. Improved surgical recovery has been realised due to
the minimal access approach, reductions in blood loss and
a favourable learning curve, compared with the conven-
tional laparoscopic technique [13–15]. Robotic outcomes
are comparable to laparoscopic approaches and superior to
open techniques [13–15]. Clinician and patient preference
for use of the dVSS in performing robotic partial
nephrectomy and prostatectomy are reflected clearly in the
increasing caseload undertaken using the platform, with
hundreds of centres now offering robotic prostatectomy
worldwide [16]. Despite advances in robotics such as
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virtual reality simulation and adaptations to instruments,
the basic configuration of the dVSS has remained relativ-
ley unchanged. Image guided surgery is well established in
urology, such as x-ray guided fluoroscopic investigation of
the urethra, bladder, ureter and reno-ureteric junction [17].
The combination of fluorescent intraoperative imaging and
robotic surgery is a logical progression in peri-operative
tissue visualisation. The fusion of minimally invasive
surgery and localised imaging has been described in the
identification of sentinel lymph nodes and renal cancer
[18, 19], super selective arterial clamping for nephron
sparing [20], and precise dissection of the prostatic neu-
rovascular bundle [21].
In healthy renal parenchyma the transporter bilitranslocase
binds ICG and healthy tissue appears isofluorescent when
perfusedwith ICG laden blood [22]. Renal tumour is deficient
in bilitranslocase and therefore appears hypofluorescent [19].
Tobis et al. noted hypofluorescent renal tumours in the pres-
ence of ICG during robotic partial nephrectomy (RAPN). The
investigators were guided by ICG in selective arterial
clamping of a handful of cases. Following this, Manny et al.
subsequently calculated hypofluorescent tissue had a sensi-
tivity of 84 % and positive predictive value of 87 % for
malignant renal lesions in 100 RAPN cases [23]. Borofsky
et al. thendescribed super selective renal artery clamping in27
patients undergoing partial nephrectomy, with ICG,
thus avoiding clamps to healthy renal parenchyma. Maximal
loss of eGFR at 3 month follow-up was 1.6 versus 14.0 % in
the non-ICG study arm [24]. Bjurlin et al. also reported a
comparatively favourable 6.2 % decrease in glomerular fil-
tration rate at 2 weeks postoperatively through the use of
super-selective arterial clamping assisted with ICG [20, 25].
Patients undergoing super selective clamping showed signif-
icantly improved renal function at follow-up, however, these
studies were underpowered and did not examine the impact of
the technology upon intraoperative decision making [25].
Robot-assisted radical prostatectomy (RARP) may be
supplemented by ICG imaging to identify the prostatic
neurovascular bundle. In 2015, Patel et al. at demonstrated
30 % of prostatic neurovascular dissections were revised
during nerve sparing RARP [21]. Given the degree of nerve
spare correlates to functional outcomes [26], ICG holds
promise for improving post-prostatectomy continence and
erectile function. Robot-assisted sentinel node harvest is
performed at RARP to determine metastatic nodal status. A
hybrid fluorescent ICG radiotracer was optimised to detect
sentinel lymph nodes in robot-assisted lymph node dissec-
tion, and improved in vivo identification through fluores-
cence to 93.5 % versus 50.0 % in non-optimised samples
(n = 38; p = 0.005) [18]. In another series, robotic ICG
assisted sentinel node harvest during RARP yielded a sen-
sitivity of 100 % and negative predictive value of 100 %
(n = 50), however, this method was non-specific. With
larger sample sizes, it is likely the diagnostic coefficients
would fall to below 100 % [27]. In spite of this, the potential
utility of ICG for metastatic node detection and differentia-
tion of oncological tissue remains encouraging.
Early work byMoore in revising surgicalmargins based on
fluorescence, and the radiolabelling of fluorescent dye to
localise oncological tissue was visionary. Recent technolog-
ical advances in cancer biomarkers and immunology have
prompted the hybridisation of ICG with cancer selective
ligands, to localise tumour by fluorescence. Prostate specific
membrane antigen (PSMA) is upregulated in prostate cancer
by 100 to 1000-fold [28, 29]. Although at the pre-clinical
stage, ICG bound PSMA-ligand was demonstrated to detect
PSMA positive prostatic tumours in mice by Nakajima et al.
using the humanised monoclonal antibody specific to PSMA,
J591 [30]. Notably the J591 antibody has been delivered in
several human clinical trials at high doses with a favourable
safety profile [31–33]. In mice with human cell line prostate
cancer, tumour was visually identifiable through fluorescence
from 1 to 10 days after administration [30]. The accurate
identification of previously indiscernible cancer tissue should
be expected to transform positive surgical margin rates, and
delay biochemical recurrence in prostate cancer. Similar
advances in renal and bladder cancer immunology may also
allow transfer of the technology to treat these pathologies.
In summary ICG combined with the dVSS is an incumbent
game changer, and has been described as a ‘‘hammer looking
for a nail’’ [25]. Evidence is emerging that ICG is useful in the
robotic surgeon’s arsenal and yields tangible clinical benefit
from selective arterial clamping in RAPN. Well-designed
randomised controlled trials are urgently needed to quantify
improvements in outcomes following ICG-augmented robotic
procedures such as sentinel node excision, and identification of
oncological tissue. It remains to be proven whether ICG brings
small, incremental procedure-specific advances, or clinically
substantial benefits to overall survival and functional recovery
to these procedures. A revolutionary step in operative imaging
though the labelling of fluorescent molecules to enhance en
bloc tumour resection was espoused nearly 70 years ago by
neurosurgeon Dr George Moore. Although at the pre-clinical
stage, it is onlyamatter of timebeforeMoore’spioneeringwork
is assimilated into routine robotic surgical practice.
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